CTLA4 and cancer: Thus, the immune checkpoint blockades (ICBs), anti-CTLA-4 and anti-PD-L1, have been employed to suppress malignant tumors and have significantly improved patient survival rates (Doroshow et al., 2021; Matias et al., 2021).